Spyre Therapeutics Inc. (SYRE)
NASDAQ: SYRE
· Real-Time Price · USD
16.90
0.04 (0.24%)
At close: Aug 15, 2025, 10:19 AM
0.24% (1D)
| Bid | 16.9 |
| Market Cap | 1.02B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -206.81M |
| EPS (ttm) | -2.53 |
| PE Ratio (ttm) | -6.68 |
| Forward PE | -4.56 |
| Analyst | Buy |
| Ask | 16.99 |
| Volume | 55,681 |
| Avg. Volume (20D) | 536,743 |
| Open | 16.96 |
| Previous Close | 16.86 |
| Day's Range | 16.87 - 17.25 |
| 52-Week Range | 10.91 - 40.26 |
| Beta | 2.83 |
About SYRE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SYRE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SYRE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-11.64%
SYRE stock has given up its prior gain. Spyre Ther...
Unlock content with
Pro Subscription
1 month ago
-11.64%
Spyre Therapeutics shares are trading higher after the company announced interim Phase 1 results from its first-in-human trials of SPY002 and SPY072.
